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Abstract
Background: Alveolar soft part sarcoma (ASPS) is a rare entity of soft tissue malignancies with uncommon spinal
involvements. Surgical management should be the best choice of cure.
Methods: Five patients with spinal ASPS were interviewed retrospectively, where data was collected. The relevant
literatures were also systematically examined. Thereafter, patient and surgical data were obtained and pooled for
prognostic analysis.
Results: A total of five patients with eight surgeries were reviewed retrospectively, and three patients previously
reported were also included. All patients were surgically treated, where five of them underwent additional adjuvant
therapies such as chemotherapy, radiotherapy, and targeted therapy in order to manage their local and/or systematic
diseases. One patient was lost in follow-up. For the remaining seven patients, the mean follow-up period was 19.7 ± 8.
8 months, two succumbed to disease while five were alive at the time of the study.
Conclusions: Surgical management is shown to be the most important and the most effective treatment strategy for
spinal ASPS, whereas adjuvant therapies made little impact. The prognostic factors for spinal ASPS are primary or
metastatic lesions, neurological status, disease progression, systematic conditions, and resection approaches.
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Background
Alveolar soft part sarcoma (ASPS), a rare entity of soft
tissue malignancies, predominantly affects young adoles-
cents and accounts for approximately 0.4–1.0% of all
soft tissue sarcomas [1, 2]. ASPS is first described by
Christopherson et al [3] in 1952 as a unique kind of tu-
mors with uncertain histogenesis. It is characterized by
pseudoalveolar, or organoid, arrangement of cells in
relation to numerous delicate endothelial-lined vascular
channels and septa. ASPS is still classified as “tumors of
uncertain differentiation” by the WHO today [4].
ASPS is a tumor with relatively indolent growth pattern,
which commonly originates from the muscles and deep
soft tissues of the trunk and the extremities; however, me-
tastases may be present at the time of presentation or
occur decades after the primary tumor resection [5–8].
The most effective treatment for ASPS is surgical excision
while en-bloc resection offers the best chance of cure.
Nevertheless, ASPS was previously reported to be refrac-
tory to chemotherapy and radiotherapy [9]. Both primary
and metastatic spinal ASPS are rarely reported in the lit-
erature. There are only sporadic case reports published,
which focus on the diagnosis and management [9–12]. In
this case series, a retrospective review was performed to
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report the preliminary experiences of the clinical features
and treatment strategies of spinal ASPS, the current litera-
tures are also systematically reviewed.
Methods
Patients review
This report retrospectively reviewed patients that were sur-
gically treated and confirmed as spinal ASPS postopera-
tively in our institution from January 2005 to December
2014. Patient and surgical data such as general information
(age and sex), radiological findings, pre- and post-operative
status, treatment strategies, operation details, complica-
tions, and pathological findings were collected. Lesion clas-
sification were classified as primary, locally recurred
(surgically treated before), or metastatic. Other organ in-
volvements and metastasis status were also documented.
Operation details including the time of surgery, intraopera-
tive blood loss, and reconstruction strategies were recorded.
Treatment strategies include surgical management and ad-
juvant therapies such as chemotherapy, radiotherapy, and
targeted therapy. The preoperative and 1-month postopera-
tive Frankel score were calculated and compared for each
patient. All patients were followed up after the surgery
(every 3 months in the first year and 6 months thereafter),
and the progression of their diseases were documented
(local recurrence, metastasis, or none). At the last follow-
up, the condition of each patient was confirmed by tele-
phone calls and classified as no evidence of disease (NED),
alive with disease (AWD), and died of disease (DOD). Per-
mission from the hospital ethics committee and written in-
formed consents from all patients were obtained before the
beginning of the study.
Literature review
The sporadic case reports on spinal ASPS are treasured as
valuable resources because the disease type being dis-
cussed and explored here is extremely rare with a very low
morbidity. A PubMed search was conducted with the
combination of the “alveolar soft part sarcoma and spine”
since 2000 using the advanced search builder. Three arti-
cles were found and all included in the current study.
Two independent researchers performed extended litera-
ture analysis fulfilling the requirement of this retrospective
review. Detailed data were obtained and were pooled
together with our clinical data; subsequent prognostic
analyses were also performed.
Results
General description
Five patients underwent a total of eight surgeries were
reviewed retrospectively, and three patients previously
reported in the literatures were also included (Table 1).
These eight patients have a mean age of 28.4 ± 8.7 years,
with a female to male ratio of 5:3. There is a total of four
sacrum and seven mobile spine lesions, symptoms in-
clude pain, numbness and weakness of the extremities,
and/or palpable mass, which were later surgically
resected. Other metastatic sites include the lung, the
scull, and the pubis. The primary site of tumors was the
sacrum for four patients, the thoracic spine for one pa-
tient, and the leg for one patient (the primary site of
patient no.8 was not available).
Treatment details
All patients were surgically treated, where five of them
also underwent adjuvant therapies such as chemother-
apy, radiotherapy, and targeted therapy to manage their
local and/or systematic diseases. All patients suffered
from neurological defects due to cord and/or radical
compression, and the majority number of patients had
their symptoms alleviated postoperatively. Nine piece-
meal and two en bloc surgeries were performed. The
time of surgery and intraoperative blood loss varies, with
an average of 301.1 ± 247.8 min (110–880) and 2162.5 ±
1395.9 ml (1000–5000), respectively. Reconstructions
were performed for all patients postoperatively except
for patient no.2 who underwent low sacrectomy.
Two patients suffered from postoperative complica-
tions. Patient no.5 was a 16-year-old girl, who developed
wound disunion and necrosis after the first surgery.
After conservative treatment for 20 days, she underwent
a second surgical procedure where her wound healed
15 days thereafter. Moreover, one patient reported by
Lizzati et al. suffered from meningocele after the en bloc
resection but made a full recovery after 40 days of
hospitalization.
Follow-up
The mean follow-up time was 19.7 ± 8.8 months (8–34).
Two patients had tumor local recurrence postoperatively
and underwent further surgical procedures. Patient no.4
was alive with disease 21 months after the second surgery,
and patient no.5 succumbed to the disease 4 months after
her third surgery (Fig. 1). The poor outcome of this 16-
year-old girl might be owing to local disease recurrence
and the early onset of distant metastasis. The rest three
patients were still alive at the time of the follow-up, where
two of them had no evidence of disease. The two patients
underwent en bloc resections and were reported earlier
had different outcomes. One died 26 months postopera-
tively while the other one was alive with no evidence of
disease after 18 months follow-up.
Discussion
ASPS is a malignant tumor, which accounts only 0.4–
1% of all soft tissue sarcomas, with a higher incidence
amongst patients between 15–35 years of age, but
rare before age 5 and after age 50 years [1, 2, 13, 14].
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The disease has obvious female predominance in the
first three decades and reverses thereafter, the re-
ported female to male ratio is approximately 2:1 and
it is well reflected in this case series [13]. Although
spinal involvements were extremely rare for ASPS,
both primary and metastatic ASPS that erode the
spinal column were represented in this report. In
metastatic ASPS, more lesions were found in the mo-
bile spines, whereas primary ASPS was more com-
monly seen in the sacrum.
The symptoms of spinal ASPS lack specificity. It may
resemble neurological defects which initially present as
pain and numbness of the innervated areas, followed by
loss of mobility and loss of sensory receptions; further-
more, in the worst cases, this may progress into paralysis
as seen in this case series as well as published literatures.
Some patients also developed a soft palpable mass at the
paraspinal areas of the buttocks. The radiological fea-
tures of spinal ASPS are consistent with lesions at other
locations but with characteristic osseous destruction plus
Fig. 1 Patient no. 5 suffered from pain in the buttock and gait abnormality for 2 months, X-ray (a), CT (b, c), and MRI (d, e) were performed
preoperatively and a large tumor in the sacrum was revealed. A fine needle biopsy confirmed ASPS where surgical resection was indicated. After
the tumor resection, screw and rod reconstruction was performed (f). The post operative histological examination (g) and the TFE3 positive
immunochemistry (h) confirmed the pathology diagnosis of ASPS. Metastasis was detected 3 months later (i) and two further surgeries were
performed. Unfortunately, this patient succumbed to the disease 5 months after the first surgery
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a paraspinal soft tissue mass [8, 15]. Magnetic resonance
(MR) images may assist in the diagnosis and differential
diagnosis of this relatively rare disease by a combination
of heterogeneous high signal on both T1- and T2-
weighted images, with or without multiple intra- or
extra-tumoral signal voids [16].
Pathological examinations, including histological and
genetic analyses, have been treated as the gold standard
diagnostic criteria and have an increased number of ap-
plications recently [1, 17, 18]. While Christopherson et
al firstly reported and named ASPS as a distinctive and
unrecognized soft tissue tumor, the histological features
of ASPS were later described by pathologists [19–21].
The most important feature of ASPS is the characteristic
ASPL/TFE3 fusion recognized using immunohistochem-
istry examinations, which is considered of great diagnos-
tic value [22].
Surgical management indeed offer the best prognosis
and should be considered the most important and the
most effective treatment strategy for spinal ASPS as pre-
viously suggested [11]. At early stages, patients are
asymptomatic; however, upon diagnosis, there have al-
ways been neurological defects and large size tumors
identified. Surgical resections can directly remove the
majority or the entirety of the tumor mass, which
quickly lead to spinal cord or radicular decompression.
This can alleviate suffering, improve the quality of life,
or even prolong life expectancy. Although en bloc resec-
tion have been widely accepted and considered to be the
best choice for soft tissue sarcomas, including ASPS, but
it was not always achievable [9, 12], this is usually due to
the large tumor size and the complexity of the local ana-
tomical structures. Spinal ASPS is always accompanied
with a large soft tissue mass, which might infiltrate into
the soft paraspinal spaces and/or erode the surrounding
vital nerve roots and vessels. Whether these structures
can be sacrificed should be cautiously considered based
on the general condition of the patient, which includes
systematic disease progression, potential prognoses, and
the preference of the patient. Although en bloc resection
may prolong survival, the sacrifice of certain vital struc-
tures may compromise the quality of life for patients. All
five patients in this review and one from the literature
underwent piecemeal resection, whereas the other two
from the literature underwent resection using an en bloc
fashion. The duration of surgery and intraoperative
blood loss ranges, from our experience, the spinal ASPS
is rich in the vessels and it was challenging to deal with
the intraoperative blood loss. Preoperative embolization
of the tumor vessels might be helpful but no conclusion
could be drawn yet. These features highlighted the diffi-
culties in the surgical management of spinal ASPS.
Unfortunately, the value of adjuvant therapies for
ASPS was limited. Four of our patients received adjuvant
therapies. In three cases, this may have helped to control
the systematic disease, but no impact was seen on the
spinal lesions. In fact, chemotherapy and radiotherapy
are more commonly considered as palliative strategies
for hospice care [23, 24]. A number of ongoing clinical
trials are focusing on the targeted therapies of ASPS, but
no conclusions can be drawn yet [25–28].
Currently, the recognized prognostic factors of ASPS
are age, tumor size, and metastases status, whereas the
histological feature is thought to have no prognostic sig-
nificance [1, 5, 29, 30]. Three patients of our cases to-
gether with one from literature had metastatic spinal
ASPS and were all successfully treated. The prognoses of
these patients can be optimistic. However, the primary
spinal ASPS may indicate a poor prognosis seen from
both of our cases and the literature. Two of the patients
with primary ASPS died while the other one (no. 3) had
a local recurrence. Furthermore, the poor prognosis of
patient no.5 may be a combination of young age, large
tumor size, rapid lesion progression, poor neurological
status, early multi-organ metastasis, ineligibility to en
bloc resection, and lack of effective adjuvant therapies.
From our preliminary clinical experience and knowledge,
it can be concluded that the poor prognostic factors for
spinal ASPS may include primary spinal lesions, severe
neurological defects, rapid lesion progression with early
metastasis, and ineligibility to en bloc resection; on the
other hand, patients with metastatic spinal lesions and
well-controlled systematic disease may have a good
prognosis. However, this conclusion requires further in-
vestigation using larger sample size due to the limitation
of small patient number in the current study.
Conclusions
In summary, this report has presented a case series of
five spinal ASPS patients and systematically reviewed re-
lated literatures. It is concluded that surgical manage-
ment is the most important and the most effective
treatment strategy for spinal ASPS while adjuvant ther-
apies had little effects. The prognostic factors for spinal
ASPS include primary or metastatic lesions, neurological
defects, disease progression, systematic conditions, and
resection approaches. The limitation of this study is the
small patient number; however, due to the rare nature of
this tumor type, clinical trials with large number of pa-
tients and randomized designs may require multi-
institutional cooperation.
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